Actuate Therapeutics, Inc. (ACTU): Cash & Equivalents
$13.16M
As of 2025-12-31
$4.43M
As of 2026-06-30
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $13.16M | +52.3% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $8.64M | n/a | 2025-03-13, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Actuate Therapeutics, Inc. (ACTU) | 2025-12-31 | $13.16M | +52.3% |
| CytoDyn Inc. (CYDY) | 2026-05-31 | $11.85M | -0.4% |
| Biovie Inc. (BIVI) | 2026-06-30 | $8.98M | -48.8% |
| Chemomab Therapeutics Ltd. (CMMB) | 2025-12-31 | $7.56M | +24.6% |
| CalciMedica, Inc. (CALC) | 2025-12-31 | $11.52M | +45.2% |
| Edesa Biotech, Inc. (EDSA) | 2025-09-30 | $10.80M | +980.0% |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $13.20M | -43.3% |
| Cingulate Inc. (CING) | 2025-12-31 | $10.95M | -10.3% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $7.80M | +440.3% |
Compare ACTU, CYDY, BIVI, CMMB side by side · Screen every company in Pharmaceutical Preparations ↗